{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:55:43Z","timestamp":1791341743392,"version":"4.3.1"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            BC-3781 is a novel semisynthetic pleuromutilin antibiotic inhibiting bacterial protein synthesis. BC-3781 has completed a phase 2 clinical trial in acute bacterial skin and skin structure infections (ABSSSI). Its antibacterial spectrum additionally covers the predominant pathogens causing community-acquired bacterial pneumonia (CABP). In this study, the antibacterial activity of BC-3781 was evaluated against a contemporary collection of 10,035 bacterial isolates predominately causing ABSSSI and CABP, among other infections, collected within the SENTRY Antimicrobial Surveillance Program worldwide in 2010. BC-3781 exhibited potent activity against organisms commonly isolated from ABSSSI such as\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.12 \u03bcg\/ml; 99.8% inhibited at \u22640.5 \u03bcg\/ml), beta-hemolytic streptococci (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.03\/0.03 \u03bcg\/ml; 99.3% inhibited at \u22640.5 \u03bcg\/ml), and coagulase-negative staphylococci (CoNS; MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.06\/0.12 \u03bcg\/ml; 97.8% inhibited at \u22641 \u03bcg\/ml). BC-3781 displayed similar MIC distributions among methicillin-susceptible (MSSA) and methicillin-resistant (MRSA)\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">S. aureus<\/jats:named-content>\n            strains. BC-3781 was also active against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Enterococcus faecium<\/jats:named-content>\n            , with 76.3% of vancomycin-susceptible and 97.0% of vancomycin-resistant isolates being inhibited at BC-3781 concentrations of \u22641 \u03bcg\/ml. Beta-hemolytic and viridans group streptococci were highly susceptible to BC-3781, with 99.3% and 96.7% of isolates inhibited at \u22640.5 \u03bcg\/ml, respectively. Further, activity of BC-3781 against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Streptococcus pneumoniae<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml),\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Haemophilus influenzae<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 1\/2 \u03bcg\/ml), and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Moraxella catarrhalis<\/jats:named-content>\n            (MIC\n            <jats:sub>50\/90<\/jats:sub>\n            , 0.12\/0.25 \u03bcg\/ml) was not negatively influenced by \u03b2-lactamase production or resistance to other antimicrobial classes tested. In all, BC-3781 displayed a very potent antibacterial profile including the most prevalent bacterial pathogens causing ABSSSI and CABP, thus warranting further clinical development of this antibiotic in these and possibly other indications.\n          <\/jats:p>","DOI":"10.1128\/aac.00358-13","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T02:42:23Z","timestamp":1373337743000},"page":"4489-4495","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":76,"title":["Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010"],"prefix":"10.1128","volume":"57","author":[{"given":"Susanne","family":"Paukner","sequence":"first","affiliation":[{"name":"Nabriva Therapeutics AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zrinka","family":"Ivezic-Schoenfeld","sequence":"additional","affiliation":[{"name":"Nabriva Therapeutics AG, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Jones","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"},{"name":"Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043252"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1308.061575"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055356"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200405-644ST"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2004.08.003"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2009.15.s2.5"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.9.2.253"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg466"},{"key":"e_1_3_2_11_2","unstructured":"EUCAST. 2012. MIC distributions. http:\/\/www.eucast.org\/mic_distributions\/."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1458-1462.2006"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2001.02595.x"},{"key":"e_1_3_2_14_2","unstructured":"FDA. 2010. Altabax (retapamulin) drug information. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm. Accessed December 2012."},{"key":"e_1_3_2_15_2","unstructured":"FDA. 2010. Tiamulin drug information. http:\/\/www.accessdata.fda.gov\/scripts\/animaldrugsatfda\/index.cfm?gb=2. Accessed December 2012."},{"key":"e_1_3_2_16_2","unstructured":"European Medicines Agency. 2011. Econor (valnemulin) European assessment report. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/veterinary\/medicines\/000042\/vet_med_000116.jsp&mid=WC0b01ac058008d7a8. Accessed December 2012."},{"key":"e_1_3_2_17_2","unstructured":"European Medicines Agency. 2012. Altargo (retapamulin) European public assessment report. http:\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124. Accessed December 2012."},{"key":"e_1_3_2_18_2","first-page":"570","article-title":"Antibiotic substances from basidiomycetes. VIII","volume":"37","author":"Kavanagh F","year":"1951","unstructured":"KavanaghFHerveryARobbinsWJ. 1951. Antibiotic substances from basidiomycetes. VIII. Pleurotus mutilus (Fr.) Sacc. & Pleurotus Passeckerianus Pilat. Proc. Natl. Acad. Sci. U. S. A. 37:570\u2013574.","journal-title":"Pleurotus mutilus (Fr.) Sacc. & Pleurotus Passeckerianus Pilat. Proc. Natl. Acad. Sci. U. S. A."},{"key":"e_1_3_2_19_2","volume-title":"Pharmacokinetic-pharmacodynamic analysis for efficacy of BC-3781 using new clinical trial endpoints in patients with acute bacterial skin and skin structure infection, poster A2-025","author":"Bhavnani SM","year":"2011","unstructured":"BhavnaniSMHammelJPRubinoCMBulikCCReynoldsDKIvezic-Sch\u00f6nfeldZWichaWWNovakRPrinceWAmbrosePG. 2011. Pharmacokinetic-pharmacodynamic analysis for efficacy of BC-3781 using new clinical trial endpoints in patients with acute bacterial skin and skin structure infection, poster A2-025. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_20_2","volume-title":"Microbiological activity and outcome of the pleuromutilin BC-3781 in a clinical phase 2 trial in acute bacterial skin and skin structure infections (ABSSSI), abstr. L-1660","author":"Paukner S","year":"2012","unstructured":"PauknerSIvezic-SchoenfeldZTackKJSahmDPrinceWT. 2012. Microbiological activity and outcome of the pleuromutilin BC-3781 in a clinical phase 2 trial in acute bacterial skin and skin structure infections (ABSSSI), abstr. L-1660. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_21_2","volume-title":"A phase 2 study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in acute bacterial skin and skin structure infections (ABSSSI), abstr. L-966","author":"Prince WT","year":"2011","unstructured":"PrinceWTObermayrFIvezic-SchoenfeldZLellCWichaWStrickmannDTackKNovakR. 2011. A phase 2 study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in acute bacterial skin and skin structure infections (ABSSSI), abstr. L-966. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL. American Society for Microbiology, Wahington, DC."},{"key":"e_1_3_2_22_2","volume-title":"Population pharmacokinetic analyses for BC-3781 using phase 2 data, poster A2-024","author":"Rubino CM","year":"2011","unstructured":"RubinoCMXueBBhavnaniSMPrinceWTIvezic-Sch\u00f6nfeldZWichaWWAmbrosePG. 2011. Population pharmacokinetic analyses for BC-3781 using phase 2 data, poster A2-024. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks001"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05789-11"},{"key":"e_1_3_2_25_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014eighth edition","author":"CLSI","year":"2009","unstructured":"CLSI. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014eighth edition. M7-A8. CLSI, Wayne, PA."},{"key":"e_1_3_2_26_2","volume-title":"Performance standards for antimicrobial susceptibility testing; approved standard; twenty-first informational supplement","author":"CLSI","year":"2012","unstructured":"CLSI. 2012. Performance standards for antimicrobial susceptibility testing; approved standard; twenty-first informational supplement. M100-S22. CLSI, Wayne, PA."},{"key":"e_1_3_2_27_2","unstructured":"EUCAST 2011. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3 January 2011. http:\/\/www.eucast.org\/clinical_breakpoints. Accessed December 2012."},{"key":"e_1_3_2_28_2","unstructured":"FDA. 2010. Tygacil label. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021821s021lbl.pdf. Accessed December 2012."},{"key":"e_1_3_2_29_2","volume-title":"Correlation of in vitro susceptibility testing results for an investigational pleuromutilin (BC-3781) using MIC and disk diffusion methods against Gram-positive pathogens, poster P913","author":"Biedenbach DJ","year":"2010","unstructured":"BiedenbachDJSaderHSPutnamSDPauknerSNovakRIvezic-SchoenfeldZJonesRN. 2010. Correlation of in vitro susceptibility testing results for an investigational pleuromutilin (BC-3781) using MIC and disk diffusion methods against Gram-positive pathogens, poster P913. 20th Eur. Congr. Clin. Microbiol. Infect. Dis., Vienna, Austria."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.09.82"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00358-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00358-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:28:59Z","timestamp":1645482539000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00358-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1128\/AAC.00358-13"],"URL":"https:\/\/doi.org\/10.1128\/aac.00358-13","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"2013-02-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}